Community-acquired pneumonia: the evolving challenge

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Rectal bacteriotherapy for recurrent Clostridium difficile-associated diarrhoea: results from a case series of 55 patients in Denmark 2000–2012 M. Tvede,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

L. Boyanova Clinical Microbiology and Infection

C.N. van Ettekoven, D. van de Beek, M.C. Brouwer

Gut bacterial microbiota and obesity

An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia A.R. Akram, J.D. Chalmers, J.K. Taylor, J. Rutherford,

Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia—a propensity-adjusted analysis G. Choudhury,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone.

J.-P. Van geertruyden Clinical Microbiology and Infection

M. Giannella, B. Pinilla, J. A. Capdevila, J. Martínez Alarcón, P

R. Cantón Clinical Microbiology and Infection

A. F. Simonetti, C. Garcia-Vidal, D. Viasus, D. García-Somoza, J

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Chlamydia trachomatis infections in heterosexuals attending sexually transmitted disease clinics in Slovenia D. Kese, M. Maticic, M. Potocnik Clinical.

V.E. Nambudiri, R.C. Dwyer, C.A. Camargo, T.S. Kupper, D.J. Pallin

P. Davey, C. Pagliari, A. Hayes Clinical Microbiology and Infection

Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia C. Carbon, S. Moola,

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

Vector control: a cornerstone in the malaria elimination campaign

Training for the infectious diseases speciality in Norway

G. Höffken Clinical Microbiology and Infection

B. Gordts Clinical Microbiology and Infection

CMI editorial report 2011 Clinical Microbiology and Infection

Bacterial resistance—the clinical challenge

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

Elements of design: the knowledge on which we build

Changes in macrolide resistance among respiratory pathogens after decreased erythromycin consumption in Taiwan P.-R. Hsueh, J.-M. Shyr, J.-J. Wu Clinical.

Levofloxacin in the treatment of ventilator-associated pneumonia

R. Bitterman, M. Paul, D. Polak, Y. Geffen

Evolving epidemiology of invasive Haemophilus infections in the post-vaccination era: results from a long-term population-based study M.R. Berndsen,

Metagenomics and probiotics

A. Bryskier Clinical Microbiology and Infection

J. Garau Clinical Microbiology and Infection

T.M. File Clinical Microbiology and Infection

Antibacterial drug discovery in the 21st century

Community-acquired pneumonia: epidemiologic and clinical consideration

Abstracts cont. Clinical Microbiology and Infection

Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis S.R. Norrby, J. Quinn, M. Rangaraju,

Effect of metronidazole versus standard care on length of stay of patients admitted with severe infectious mononucleosis: a randomized controlled trial

Current experience in treating invasive zygomycosis with posaconazole

Reducing antibiotic use in influenza: challenges and rewards

Gender differences in the outcome of community-acquired Staphylococcus aureus bacteraemia: a historical population-based cohort study J. Smit, L.E. López-Cortés,

Correlation between time to positivity of blood cultures with clinical presentation and outcomes in patients with Klebsiella pneumoniae bacteraemia: prospective.

Statin use and clinical outcomes among pneumonia patients

Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin G. Drusano Clinical Microbiology and Infection

Clinical Microbiology and Infection

Listeriosis: a resurgent foodborne infection

Overview of cefixime use in community-acquired infections

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia U. Hohenthal, S. Hurme, H. Helenius,

The atypical pneumonias: clinical diagnosis and importance

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre R.R. Laffer, P. Graber, P.E. Ochsner, W. Zimmerli

Abstracts Clinical Microbiology and Infection

Virology: a scientific discipline facing new challenges

Serum ferritin levels in West Nile encephalitis

Modelling during an emergency: the 2009 H1N1 influenza pandemic

New oral cephalosporins in pediatric community-acquired infections

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Community-acquired acute bacterial meningitis in the elderly in Turkey

Joshua P. Metlay, Daniel E. Singer Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

CMI readers' survey Clinical Microbiology and Infection

Rajko Saletinger, Mario Poljak, Franc Strle

The future of diagnostic bacteriology

Presentation transcript:

Community-acquired pneumonia: the evolving challenge R. Finch Clinical Microbiology and Infection Volume 7, Pages 30-38 (January 2001) DOI: 10.1046/j.1469-0691.2001.0070s3030.x Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

Fig 1 Clinical and bacteriological outcome for high-risk subpopulations of patients with community-acquired pneumonia treated with telithromycin 800 mg once daily for 7–10 days. aDocumented pneumococcal bacteremia. Clinical Microbiology and Infection 2001 7, 30-38DOI: (10.1046/j.1469-0691.2001.0070s3030.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

Fig 2 Adverse events occuring in > 2% of patients with community-acquired pneumonia treated with telithromycin 800 mg once daily or comparator in controlled trials (modified intent-to-treat population). Clinical Microbiology and Infection 2001 7, 30-38DOI: (10.1046/j.1469-0691.2001.0070s3030.x) Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions